Detail akcie CEL-SCI Rg online

Business Summary: CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Financial Summary: BRIEF: For the fiscal year ended 30 September 2025, CEL-SCI Corp revenues was not reported. Net loss applicable to common stockholders decreased 8% to $25.4M. Lower net loss reflects Research and development decrease of 13% to $15.9M (expense), Int exp on Financial Lease liab. decrease of 11% to $800K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$15.31 to -$6.27.